Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

ABSTRACT:

SUBMITTER: Cheah CY 

PROVIDER: S-EPMC5161005 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature